Maintenance Therapy in HER2+ Metastatic Breast Cancer Program

Pfizer Inc. has released a Request for Proposals (RFP) dated August 13, 2025, under its Independent Medical Education competitive grant program, focusing on maintenance therapy in HER2-positive metastatic breast cancer (MBC). This program is part of Pfizer’s broader commitment to supporting independent educational initiatives that address gaps in healthcare professional knowledge and ultimately improve patient outcomes. Pfizer will not be involved in project development or execution, as all funded projects must remain fully independent. The grants are intended to fund educational programs within the United States that enhance clinical understanding of evolving treatment strategies for HER2-positive MBC patients. The scope of the RFP emphasizes the need to improve knowledge about the role of maintenance therapy in first-line HER2-positive MBC settings. Key areas include the current standard of care informed by the CLEOPATRA trial, integration of maintenance therapy with endocrine therapy for hormone receptor-positive/HER2-positive patients, and therapy combinations differentiated by hormone receptor status. Applicants are also encouraged to address evolving treatment paradigms, safety profiles, adverse event management, sequencing and re-treatment algorithms, and updates from the latest clinical data. Acceptable educational formats range from conference symposia, grand rounds, and peer-to-peer education, to digital platforms such as webinars, podcasts, and infographics. Clinical research and projects evaluating therapeutic efficacy will not be considered. Eligible applicants must be U.S.-based organizations such as medical, allied health, or pharmacy schools; hospitals and healthcare institutions; professional organizations and medical societies; and medical education companies. Individual applicants and physician-owned practices are ineligible. The applicant organization must be legally able to receive funding directly from Pfizer, and for continuing education projects, the applying organization must serve as the accrediting body. If multiple institutions are involved, all must contribute significantly, with the lead applicant serving as project/program lead. The lead individual must be an employee or contractor of the requesting organization. Grant applications must be submitted through the Pfizer CyberGrants portal by October 1, 2025, no later than 23:59 Eastern Standard Time. The application must include responses to required questions and a project proposal, uploaded under the General RFP Submission field. Required sections include goals and objectives, needs assessment, target audience, project design and methods, innovation, evaluation and outcomes, dissemination plan, anticipated timeline, organization detail, and budget narrative. Applicants should ensure that organizational information is up to date in the portal before submission. Late submissions will not be reviewed. Funding amounts for individual projects may range from $10,000 to $250,000, with a total estimated budget of $500,000 available for this RFP. Award amounts may include direct costs, indirect costs, and institutional overheads up to 28 percent as per Pfizer policy. Approved institutions will be required to enter into a grant agreement with Pfizer, and payment will only be made to the grantee organization. Grants are expected to support projects beginning in December 2025 and ending around May 2027, with a preferred project duration of approximately 18 months, though flexibility is allowed. Award notifications are anticipated by October 31, 2025, following Pfizer’s internal review process. The target audience for these educational initiatives includes community medical oncologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care of MBC patients. Applications will be reviewed internally by Pfizer, with all applicants notified via email. Questions regarding the RFP should be submitted in writing to the designated grant officer, Lori Carpenter, at lori.carpenter@pfizer.com, with the subject line “2025 ONC US Maintenance MBC RFP.” Technical assistance is available through the CyberGrants portal. This program represents Pfizer’s commitment to advancing education that aligns with its scientific strategies while remaining independent in execution:contentReference[oaicite:0]{index=0}.

Ensure portal profile is updated and submit early to avoid cancellation; late applications not accepted